Measurement of Tumor “Size” in Recurrent Malignant Glioma: 1D, 2D, or 3D?

References

1. ↵
   Chow KL, Gobin YP, Cloughesy T, et al. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol 2000;21:471–478

   Abstract/FREE Full Text
2. ↵
   Reeves GI, Marks JE. Prognostic significance of lesion size for glioblastoma multiforme. Radiology 1979;132:469–471

   CrossRefPubMed
3. ↵
   Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988;6:338–343

   Abstract
4. ↵
   Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–214

   CrossRefPubMedWeb of Science
5. ↵
   Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–1280

   Abstract
6. ↵
   Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216

   Abstract/FREE Full Text
7. ↵
   Gregor A, Lind M, Newman H, et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma: RMP-7 European Study Group. J Neurooncol 1999;44:137–145

   CrossRefPubMed
8. ↵
   Cox DR. Regression models and life tables. J R Statist Soc B 1972;34:187–220
9. ↵
   Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572

   Abstract/FREE Full Text
10. ↵
    Bland M. An introduction to medical statistics. Oxford: Oxford University Press;2000 :272
11. ↵
    Warren KE, Patronas N, Aikin AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001;93:1401–1405

    Abstract/FREE Full Text
12. ↵
    Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987;62:450–459

    CrossRefPubMedWeb of Science
13. ↵
    Gurland J, Johnson RO. How reliable are tumor measurements? JAMA 1965;194:973–978
14. Chisholm RA, Stenning S, Hawkins TD. The accuracy of volumetric measurement of high-grade gliomas. Clin Radiol 1989;40:17–21

    CrossRefPubMedWeb of Science
15. ↵
    Warr D, McKinney S, Tannock I. Influence of measurement error on response rates. Cancer Treat Rep 1985;69:1127–1132

    PubMed
16. ↵
    Clarke LP, Velthuizen RP, Clark M, et al. MRI measurement of brain tumor response: comparison of visual metric and automatic segmentation. Magn Reson Imaging 1998;16:271–279

    CrossRefPubMed
17. ↵
    Fornage BD. Measuring masses on cross-sectional images. Radiology 1993;187:289

    PubMedWeb of Science
18. ↵
    Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index: a report of the Medical Research Council Brain Tumour Working Party. J Neurooncol 1990;9:47–55

    CrossRefPubMed